EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Emerging SARS-CoV-2 Variants in Uganda in the Era of COVID-19 Vaccination

Nicholas Bbosa iD, Ronald Kiiza, Alfred Ssekagiri iD, Hamidah Suubi Namagembe, Stella Esther Nabirye, Danstan Kabuuka, Cleophous Rwankindo iD, Annet Kisakye iD, Yonas T Woldemariam, Sylvia Kusemererwa iD, Terry A Ongaria iD, Ayoub Kakande und 12 weitere

Viruses · 2024

DOI: 10.3390/v16121860 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Nicholas Bbosa und 23 weiteren Autor:innen. Beteiligte Einrichtung: MRC/UVRI & LSHTM Uganda Research Unit, Entebbe 256, Uganda. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2, COVID-19 Vaccines, Phylogeny. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: World Health Organization, World Health Organization (WHO) and Bill & Melinda Gates Foundation, Bill and Melinda Gates Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The emergence of SARS-CoV-2 variants has heightened concerns about vaccine efficacy, posing challenges in controlling the spread of COVID-19. As part of the COVID-19 Vaccine Effectiveness and Variants (COVVAR) study in Uganda, this study aimed to genotype and characterize SARS-CoV-2 variants in patients with COVID-19-like symptoms who tested positive on a real-time PCR. Amplicon deep sequencing was performed on 163 oropharyngeal/nasopharyngeal swabs collected from symptomatic patients. Genome assembly, lineage classification and phylogenetic analysis was performed using the Edge Bioinformatics pipeline version 2.4.0, Pangolin version 4.3.1 and iqtree version 2.3.6 software respectively. Of the 163 deep sequences analyzed between April 2023 and March 2024, the most common were XBB.1 lineages and sublineages (113, 69.3%), followed by JN.1* (12, 7.4%), XBB.2* (11, 6.7%) and FL* (11, 6.7%), EG* (7, 4.3%), others (BQ.1.1, FY.4.1, FY.4.1.2, GY.2.1, HK.27.1) (5, 3.1%) and CM* (4, 2.5%). XBB.1* dominated from April to July 2023; thereafter, other variants, including JN.1* were increasingly detected. There was no statistically significant association between vaccine status and lineage assignment (Fisher’s exact test, p-value = 0.994). Our findings showed that the Omicron variant, specifically the XBB.1* lineage, was the dominant circulating virus. However, the emergence of the JN.1 variant that exhibits a significant spike protein mutation profile could impact COVID-19 transmission in Uganda.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19SARS-CoV-2COVID-19 VaccinesPhylogenyHumansUgandaGenome, ViralVaccinationMaleFemaleMutationAdultHigh-Throughput Nucleotide Sequencing

Stichwörter der Autor:innen

COVID-19SARS-CoV-2next-generation sequencingomicronvaccinevariants

Substanzen

COVID-19 Vaccines

Autor:innen und Institutionen

  • MRC/UVRI & LSHTM Uganda Research Unit, Entebbe 256, Uganda.
  • Uganda Virus Research Institute, Entebbe 256, Uganda.
  • Department of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London WC1E 7HT, UK.
  • World Health Organization (WHO) Country Office, Kampala 256, Uganda.
  • Department of Infectious Diseases Epidemiology, London School of Hygiene & Tropical Medicine, London WC1E 7HT, UK.
  • Ministry of Health, Kampala 256, Uganda.

ORCID-Profile: Nicholas Bbosa, Alfred Ssekagiri, Cleophous Rwankindo, Annet Kisakye, Sylvia Kusemererwa, Terry A Ongaria, Henry Kyobe Bosa, James Humphreys, Sandra Cohuet, Eugene Ruzagira, Deogratius Ssemwanga

Förderung

  • World Health Organization
  • World Health Organization (WHO) and Bill & Melinda Gates Foundation
  • Bill and Melinda Gates Foundation

Zitieren

APA

Bbosa, N., Kiiza, R., Ssekagiri, A., Namagembe, H. S., Nabirye, S. E., Kabuuka, D., Rwankindo, C., Kisakye, A., Woldemariam, Y. T., Kusemererwa, S., Ongaria, T. A., Kakande, A., Abaasa, A., Kimbugwe, G., Bosa, H. K., Driwale, A., Mwenda, J. M., Worwui, A. K., Humphreys, J., …, & Ssemwanga, D. (2024). Emerging SARS-CoV-2 Variants in Uganda in the Era of COVID-19 Vaccination. Viruses. https://doi.org/10.3390/v16121860

Vancouver

Bbosa N, Kiiza R, Ssekagiri A, Namagembe HS, Nabirye SE, Kabuuka D, et al. Emerging SARS-CoV-2 Variants in Uganda in the Era of COVID-19 Vaccination. Viruses. 2024. doi:10.3390/v16121860

BibTeX
@article{Bbosa2024,
  author = {Bbosa, Nicholas and Kiiza, Ronald and Ssekagiri, Alfred and Namagembe, Hamidah Suubi and Nabirye, Stella Esther and Kabuuka, Danstan and Rwankindo, Cleophous and Kisakye, Annet and Woldemariam, Yonas T and Kusemererwa, Sylvia and Ongaria, Terry A and Kakande, Ayoub and Abaasa, Andrew and Kimbugwe, Geofrey and Bosa, Henry Kyobe and Driwale, Alfred and Mwenda, Jason M and Worwui, Archibald K and Humphreys, James and Cohuet, Sandra and Elliott, Alison M and Ruzagira, Eugene and Kaleebu, Pontiano and Ssemwanga, Deogratius},
  title = {Emerging SARS-CoV-2 Variants in Uganda in the Era of COVID-19 Vaccination},
  journal = {Viruses},
  year = {2024},
  doi = {10.3390/v16121860}
}
Kostenlos starten →